Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
FLAMSA provides an efficient disease control in intermediate- and high-risk AML. Rate of leukemia-free survival at 2 years was 52.8% (95% CI, 46.4% to 59.2%). Rate of overall survival at 2 years was 56.1% (95% CI, 49.7% to 62.6%).